Shenzhen SiBiono GeneTech Co. Ltd.

TUCSON, Ariz., Oct. 19, 2023 /PRNewswire/ -- Derek Gwaltney has been with Sabino Recovery since 2021 and has been an integral part of the business development team since then. In his role as VP of Business Development, Gwaltney's dedication to Sabino's mission and purpose has not only led to the growth of the team, but also helped expose Sabino on a national level. Gwaltney has over 15 years of experience in the behavioral health industry and is committed to spreading the word about Sabino's individualized treatment approach and helping families find the care they need for their loved ones. Continue Reading "I'm honored to be promoted to CMO and excited for T&R Recovery's continued growth." -Derek Gwaltney Post this VP of Business Development at Sabino Recovery, Derek Gwaltney, promoted to Chief Marketing Officer of T&R Recovery Group. Gwaltney's promotion to CMO will be with T&R Recovery Group, a private corporate umbrella company that holds Sabino Recovery in Tucson, AZ, as well as their sister facility, Cypress Lake Recovery, located just outside of Houston, TX. As Chief Marketing Officer, Gwaltney will oversee all aspects of each property's business development, sales, marketing, and admissions operations. Gwaltney's experience in behavioral health, passion for helping those struggling with trauma, and his servant leadership style make him not only the perfect fit for this position but an asset to the leadership team. "Derek has been an incredible asset since he joined the team," said CEO Thomas Isbell. "Derek encompasses all the qualities that we search for in a leader and brings invaluable experience to T&R Recovery Group." Gwaltney is both humbled and excited to take on the new challenge and is committed to continuing to serve through a servant leadership lens, develop his team, and ensure that helping people struggling with trauma and addiction remains at the forefront of everything he does. "I'm honored to be promoted to CMO and excited for T&R Recovery's continued growth," said Gwaltney. "With renovations happening at Sabino, the launch of our First Responder Program at Cypress Lake Recovery and more acquisitions on the horizon, we've got a lot to be excited about and I look forward to continuing to develop and grow the team." Roy Serpa, T&R Recovery's Chairman of the Board, stated, "When I think of Derek, I truly think of a leader constantly setting the example of servant leadership to his team and all other Sabino Recovery and Cypress Lake Recovery employees. Derek has brought his 20 years of sales and marketing experience to T&R Recovery Group, he is dedicated to growing his team and continuing his part in expanding T&R Recovery's reach in the recovery world." About Sabino Recovery Located in Tucson, AZ, Sabino Recovery offers upscale trauma, mental health, and addiction residential treatment, focused on individualized care in a private and comfortable setting. We pride ourselves in our expertise at identifying and treating trauma and addictions through viewing the entire person, not just the symptoms. Our clinically sophisticated team collaborates with each person to create a personalized treatment plan tailored to their specific presenting circumstances. Our integrative model provides a safe and supportive environment for individuals to transcend their maladaptive patterns of behavior to reconnect with their authentic selves. About Cypress Lake Recovery Located just outside of Houston, TX, Cypress Lake Recovery offers holistic inpatient treatment for drug and alcohol addiction. They also offer a First Responder treatment program for addiction and trauma. Our trained substance addiction and abuse experts create individualized treatment plans for each person who comes through our doors. We focus on treating the mind, body, and spirit of each person and are never judgmental. Our goal is to carefully steer you away from unhealthy behaviors and help you reconnect with your loved ones. CONTACT: digital@sabinorecovery.com SOURCE T&R Recovery Group

North America To Be The Most Lucrative Gene Therapy Landscape, Yielding 56% Revenue “As the incidence of various chronic and lifestyle induced ailments increase, healthcare providers are looking out for advanced gene therapy options to develop effective diagnosis and therapeutics, furthering R&D at various levels,” remarks a Fact.MR analyst. Fact.MR – A Market Research and Competitive Intelligence Provider: The global gene therapy market advocates that the industry is poised to incline at an 18.5% value CAGR from 2022-2032, expected to close at a valuation of US$ 10.1 Billion. As of 2022, the market is poised to reach US$ 1.85 Billion in value terms. Rising quest to search for breakthroughs in medical treatments have been fueling demand for gene therapy of various grades. During the 2015-2021 historical period, the market experienced an incline at a value CAGR of 18.7%, closing at a value of US$ 1.55 Billion. Demand further accelerated during the COVID-19 pandemic, as healthcare providers were scrambling to develop powerful vaccines to counter the outbreak. Moreover, key healthcare providers leveraged advanced gene therapeutics to initiate clinical trials for key drug candidates. For more insights into the Market, Get A Sample of this Report! It is expected that oncology research will likely open up lucrative growth prospects for gene therapy providers. According to Globocan 2020, an estimated 19 million new cancer cases and 9,958,133 cancer deaths were reported worldwide in 2020. Various gene therapy strategies are currently being used in the treatment of cancer. These include anti-angiogenic gene therapy, pro-drug activating suicide gene therapy, immune modulation based on gene therapy, oncolytic virotherapy, gene defect correction/compensation, antisense, genetic manipulation of apoptotic and tumor invasion pathways, and RNAi strategies. Key Takeaways from the Market Study By product, yescarta-based gene therapy is likely to yield 44.5% market revenue until 2032 Luxturna-based gene therapy to garner a 36% revenue share by 2032 Europe to emerge as one of the most opportunistic gene therapy market, inclining at over 19% CAGR APAC market was valued at US$ 351 Million in 2021, poised to flourish at an 18.3% CAGR Global gene therapy market is forecast to grow over 5x from 2022 to 2032 For Comprehensive Insights Ask An Analyst Here Competitive Landscape The global gene therapy market is fiercely competitive, with only a few major players. Companies like Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd., Spark Therapeutics (Roche AG), and UniQure N.V., have a sizable market share in the Gene Therapy market. In October 2021, the National Institutes of Health, the United States Food and Drug Administration, ten pharmaceutical companies, and five non-profit organizations announced a collaboration to accelerate the development of gene therapies for the 30 million Americans who suffer from a rare disease. Such initiatives are expected to boost demand for gene therapy. BioMarin Pharmaceutical Inc. reported updates on its investigational gene therapy programs in clinical development in February 2022. The Food and Drug Administration (FDA) issued additional requests to the Company for information needed to resolve the clinical hold of the PHEARLESS Phase 1/2 study of BMN 307 issued in September 2021. Key Segments Covered in Gene Therapy Industry Research Gene Therapy Market by Product: Yescarta-based Gene Therapy Kymriah-based Gene Therapy Luxturna-based Gene Therapy Strimvelis-based Gene Therapy Gendicine Others Gene Therapy Market by Application: Ophthalmology Oncology Adenosine Deaminase/Deficient Severe Combined Immunodeficiency (ADA-SCID) Gene Therapy Market by Region: North America Latin America Europe East Asia South Asia MEA Get Customization on this Report for Specific Research Solutions More Valuable Insights Fact.MR, in its new offering, presents an unbiased analysis of the global gene therapy market, presenting historical analysis from 2015 to 2021 and forecast statistics for the period of 2022-2032. The study reveals essential insights on the basis of product (yescarta, kymriah, luxturna, strimvelis, gendicine and others), and application (ophthalmology, oncology and adenosine deaminase/deficient severe combined immunodeficiency (ADA-SCID)) across six major regions (North America, Latin America, Europe East Asia, South Asia & Oceania and Middle East & Africa). Fact.MR’s Domain Knowledge in Healthcare Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions. Check out more studies related to Healthcare Industry, conducted by Fact.MR: Huntington's Disease Treatment Market - Huntington's Disease Treatment Market Analysis by Treatment (Symptomatic Treatment of Huntington's disease, Disease-Modifying Therapies for Huntington's disease), by Region - Global Forecast 2022-2032 Animal Vaccines Market - Animal Vaccines Market Analysis by Product (Attenuated, Recombinant, DNA, Inactivated, Subunit Animal Vaccines), by Animal Type (Livestock, Companion Animal Vaccines), by Route of Administration (Subcutaneous, Intranasal, Intramuscular) & Regional Forecast 2022-2032 Amniotic Membrane Market - Amniotic Membrane Market Analysis by Product (Cryopreserved, Dehydrated Amniotic Membrane), by Application (Surgical Wounds, Ophthalmology), by End Use, by Region - Global Forecast 2022-2032 Mental Health Apps Market - Mental Health Apps Market Analysis by Platform Type (Mental Health Apps for Android, iOS), by Application Type (Depression and Anxiety Management, Stress Management, Meditation Management, Wellness Management), by Region - Global Forecast 2022-2032 Aesthetic Medicine Market - Aesthetic Medicine Market Analysis by Procedure Type (Invasive Procedures, Non-Invasive Procedures), by Region - Global Forecast 2022-2032 Regulatory Affairs Outsourcing Market - Regulatory Affairs Outsourcing Market by Services (Regulatory Consulting Outsourcing, Legal Representation Outsourcing), by Category (Drugs, Biologics), by Indication (Oncology, Neurology, Radiology), by Stage (Pre-Clinical, Clinical), by Company Size, by End Use & Regional Forecast 2022-2032 3D Printing Medical Devices Market - 3D Printing Medical Devices Market Analysis by Product Type (3D Printers, 3D Bio-Printers, Materials, Software & Services), by Technology (Laser Beam Melting, Photo Polymerization, Electron Beam Melting, Droplet Deposition), by Application, by End-User & Regional Forecast 2022-2032 mHealth Apps Market - mHealth Apps Market Analysis by Product Type (Medical Apps [Women's Health Apps, Personal, Health Record Apps, Medication Management Apps, Diagnostic Apps], Fitness Apps [Diet & Nutrition, Exercise & Fitness, Lifestyle & Stress]), by Region - Global Forecast 2022-2032 Biotechnology & Pharmaceutical Services Outsourcing Market - Biotechnology & Pharmaceutical Services Outsourcing Market Analysis by Service (Product Testing & Validation, Training & Education, Product Design & Development, Product Maintenance, Regulatory Affairs, Consulting), by End Use & Region - Global Forecast 2022-2032 Electronic Health Records Market - Electronic Health Records Market Analysis by Product (Client-server-based HER, Web-based HER), by Type (Acute, Ambulatory, Post-acute Electronic Health Records), by Business Model, by End Use, by Region - Global Forecast 2022-2032 About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 Email: sales@factmr.com Tel: +1 (628) 251-158

DUBLIN, June 20, 2022 /PRNewswire/ -- The "Gene Therapy Global Market Report 2022: By Gene, By Vector, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering. The global gene therapy market is expected to grow from $5.77 billion in 2021 to $7.37 billion in 2022 at a compound annual growth rate (CAGR) of 27.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $21.25 billion in 2026 at a CAGR of 30.3% The gene therapy market consists of sales of gene therapy related services by entities (organizations, sole traders and partnerships) that manufacture gene therapy drugs. Gene therapy is used to replace faulty genes or add new genes to cure disease or improve the body's ability to fight disease. Only goods and services traded between entities or sold to end consumers are included. The main types of gene therapy are antigen, cytokine, suicide gene and others. Antigen is a poison or other foreign substance that triggers an immunological response in the body, including antibody formation. The different vectors include viral vector, non-viral vector, others and is used in oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, others. it is implemented in various sectors such as hospitals, homecare, specialty clinics, others. Incidences of cancer and other target diseases have been increasing significantly, which is calling for effective treatments, driving the growth of the gene therapy market. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the gene therapy market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for the gene therapy market over the forthcoming years. Gene therapy is one of the most effective treatments in oncology. In this treatment, new genes are introduced into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of cancer. For instance, in September 2019, RMIT University, Australia has found that non-viral gene therapy can be used to speed up cancer research, which can bring patient-friendly cancer treatment in the market. The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer and other diseases has influenced the health conditions of the population and has led to a low average life expectancy. Luxturna, a one-time treatment for acquired retinal eye disease, costs $850,000 in the US and £613,410 in the UK, despite a markdown that is applied through Britain's National Health Service. Zolgensma, for spinal muscular atrophy, is valued at $2.1 million in the US and Zynteglo, which focuses on a rare genetic blood disorder, costs $1.78 million, thus restraining the growth of the market. The use of machine learning and artificial intelligence is gradually gaining popularity in the gene therapy market. Artificial intelligence (AI) is the simulation of human intelligence in machines, which are programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the gene therapy market to conduct a detailed analysis of all relevant data, provide insights between tumor and immune cell interactions, and offer a more accurate evaluation of tissue samples often conflicted between different evaluators. It is also expected to reduce turnaround time and also the cost of gene therapies. Major players in the gene therapy market are Novartis AG Bluebird Bio, inc. Spark Therapeutics, inc. Audentes Therapeutics Voyager Therapeutics Applied Genetic Technologies Corporation UniQure N.V. Celgene Corporation Cellectis S.A. Sangamo Therapeutics Gilead Lifesciences, inc. Orchard Therapeutics Sibiono GeneTech Co., Ltd. Gensight Biologics S.A. Shanghai Sunway Biotech Co., Ltd. Biogen Sarepta Therapeutics, inc. Sangamo Therapeutics Audentes Therapeutics Regenxbio, inc. Gegenxbio, inc. Oxford BioMedica plc. Dimension Therapeutics, inc. Bristol-Myers Suibb Company Sanofi Taxus Cardium Pharmaceuticals Group, inc. (Gene Biotherapeutics) Shrine plc. Benitech Biopharma Transgene Epeius Biotechnologies Corp. Calimmune, inc. Key Topics Covered: 1. Executive Summary 2. Gene Therapy Market Characteristics 3. Gene Therapy Market Trends And Strategies 4. Impact Of COVID-19 On Gene Therapy 5. Gene Therapy Market Size And Growth 5.1. Global Gene Therapy Historic Market, 2016-2021, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Gene Therapy Forecast Market, 2021-2026F, 2031F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market 6. Gene Therapy Market Segmentation 6.1. Global Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Antigen Cytokine Suicide Gene Others 6.2. Global Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Viral Vector Non-Viral Vector Others 6.3. Global Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Oncological Disorders Rare Diseases Cardiovascular Diseases Neurological Disorders Infectious Diseases Others 6.4. Global Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Hospitals Homecare Specialty Clinics 7. Gene Therapy Market Regional And Country Analysis 7.1. Global Gene Therapy Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion 7.2. Global Gene Therapy Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets